
The Leakage Economy: Why Hospital Finance AI Is Moving From Denials to Contracts
Dr. Dereck Mush, MD, MBAVenture fund
ARCH began in 1986 as the Argonne Chicago Development Corporation, set up by the University of Chicago and Argonne National Laboratory to turn research into companies, and became an independent venture partnership in 1992. The firm works from Chicago and Seattle and says it has invested as little as $50,000 and as much as hundreds of millions of dollars in a single company. Cofounder Robert Nelsen seeded Illumina and sits on boards including insitro and Xaira Therapeutics. HTS has covered ARCH leading Trase's $107 million seed round for AI agents that handle hospital administrative work such as faxes.
ARCH Venture Partners builds and backs science companies, mostly in biotechnology, often from the very first check.
How ARCH Venture Partners got here, step by step.
1986
The University of Chicago and Argonne National Laboratory set up ARCH to commercialize research.
1992
ARCH Venture Partners forms as a private venture partnership.

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring